Evidence map›Paper›PMID 28978141›Full record

ArticleOncotarget2017

Stephan Arni, Thi Hong Nhung Le, Rik de Wijn, Refugio Garcia-Villegas, Martjin Dankers, Walter Weder, Sven Hillinger

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Stephan ArniDepartment of Thoracic Surgery, University Hospital Zürich, Zürich, Switzerland.
Thi Hong Nhung LeDepartment of Thoracic Surgery, University Hospital Zürich, Zürich, Switzerland.
Rik de WijnPamGene International B.V., 's-Hertogenbosch, The Netherlands.
Refugio Garcia-VillegasDepartment of Physiology, Biophysics and Neuroscience, Centro de Investigación y de Estudios Avanzados del IPN, Mexico City, Mexico.
Martjin DankersPamGene International B.V., 's-Hertogenbosch, The Netherlands.
Walter WederDepartment of Thoracic Surgery, University Hospital Zürich, Zürich, Switzerland.
Sven HillingerDepartment of Thoracic Surgery, University Hospital Zürich, Zürich, Switzerland.
University Hospital of Zurich · CHPamGene (Netherlands) · NLInstituto Politécnico Nacional · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite constant improvement in existing therapeutic efforts, the overall survival rate of lung cancer patients remains low. Enzyme activities may identify new therapeutically targetable biomarkers and overcome the marked lack of correlation between cellular abundance of translated proteins and corresponding mRNA expression levels. We analysed tyrosine kinase activities to classify lung adenocarcinoma (LuAdCa) resection specimens based on their underlying changes in cellular processes and pathways that are agents of or result from malignant transformation. We characterised 71 same-patient pairs of early-stage LuAdCa and non-neoplastic LuAdCa resection specimen lysates in the presence or absence of a tyrosine kinase inhibitor. We performed

Indexed as

lung adenocarcinomamethodology for proteomicsmolecular markers of metastasis and progressionprotein activity microarraysprotein tyrosine kinase

Identifiers

PMID28978141
PMCPMC5620281
OpenAlexW2741150171

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.